MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

Is Bristol Myers Squibb's New Multiple Myeloma Drug a Game Changer

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now

1 months ago

Why Are Barclays Analysts Bullish on Eli Lilly and Bristol-Myers Squibb

1 months ago

Is Roche's Fenebrutinib a Game Changer for Multiple Sclerosis Treatment

1 months ago

Is Target's New Turnaround Strategy a Game Changer

3 weeks ago

Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?

Bristol Myers Squibb's Opdivo label expansions reflect the pharmaceutical industry's focus on growing oncology franchises amidst increasing competition and pipeline development.

BMY

Stock News•3 weeks ago

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb announced positive Phase 3 data from the SUCCESSOR-2 study involving oral mezigdomide for relapsed or refractory multiple myeloma.

BMY

Stock News•1 months ago

Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies

ImmunityBio's recently approved cancer drug shows momentum, but the stock faces risk due to valuation concerns and clinical/regulatory uncertainty.

IBRX

Stock News•2 months ago

Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?

Novo Nordisk's FDA-approved Wegovy pill is the first oral GLP-1 weight loss therapy, expected to revive momentum and reshape competition starting in 2026.

NVO